Published on 29 May 2024 on Insider Monkey via Yahoo Finance

Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy?

We recently compiled the list of the 10 Best Fast Growth Stocks To Buy according to the hedge funds using the latest sentiment data. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other fast growth stocks. Sarepta Therapeutics recently beat earnings expectations. They are the leader in gene therapy for Duchenne muscular dystrophy. They recently submitted a BLA supplement to expand the labeled population for their Duchenne gene therapy. The FDA recently informed Sarepta that they will imminently provide a draft label.

Growth stocks are those that are either growing their revenue in mid to high double or triple digit percentages or those who trade at significantly higher prices when compared to their earnings. Using a high P/E ratio is the more commonly accepted definition of growth stocks, and sometimes, investors are richly rewarded for their faith.